天演药业上涨10.09%，报2.51美元/股，总市值1.18亿美元

Core Insights - Tianyan Pharmaceutical (ADAG) experienced a 10.09% increase in stock price, reaching $2.51 per share, with a total market capitalization of $118 million as of August 22 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be $103,200, a significant decrease of 99.43% year-over-year [1] - The net profit attributable to the parent company is expected to be -$33.4241 million, reflecting a year-over-year decline of 76.41% [1] Company Overview - Tianyan Pharmaceutical is a platform-driven biopharmaceutical company focused on the development of clinical products, particularly in cancer immunotherapy [1] - The company utilizes a combination of computational biology and artificial intelligence to create novel antibodies with high safety and efficacy [1] - The "Dynamic Precision Library" serves as the company's antibody discovery engine, driving the development of its product pipeline aimed at creating globally innovative or best-in-class products [1]